| Biomarker ID | 1886 |
| PMID | 30623593 |
| Year | 2018 |
| Biomarker | Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4; Keratin type I cytoskeletal 10; SCO†spondin; Serum amyloid Pâ€component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain Vâ€IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein Aâ€I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4 (0.2 fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain Vâ€III region BRO (0.2 fold); Ig gammaâ€2 chain C region (0.2 fold); Ig gammaâ€3 chain C region (0.2 fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) |
| Type of Biomarker | Diagnostic |
| Cohort | Serum samples from African American and Caucasian PCa patients and matched healthy donors were collected after patients’ consents |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |